TransMedics Group, Inc.
About TransMedics Group, Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $605.5M
- Net income
- $190.3M
- Total assets
- $1.1B
- Market cap
- $2.4B
- Gross margin
- 59.9%
- Operating margin
- 17.9%
- Net margin
- 31.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $605.5M
- Cost of revenue
- $242.7M
- Gross profit
- $362.8M
- Operating expenses
- $254.2M
- Operating income
- $108.6M
- Income tax
- -$82.8M
- Net income
- $190.3M
- EPS (basic)
- $5.60
- EPS (diluted)
- $4.87
Balance sheet
- Total assets
- $1.1B
- Current assets
- $637.8M
- Total liabilities
- $595.3M
- Current liabilities
- $89.3M
- Shareholders’ equity
- $473.1M
Cash flow
- Operating cash flow
- $192.8M
- Investing cash flow
- -$59.3M
- Financing cash flow
- $16.9M
- Net cash flow
- $151.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.4B
- P/E ratio
- 14.6
- EPS (diluted)
- $4.87
- Shares outstanding
- 33.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 2, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $190.3M in FY2025.
- Revenue grew 2262% from FY2020 to FY2025.
- Gross margin of 59.9%, net margin 31.4%.
- Trading 53% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 14.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TransMedics Group, Inc..
Write a review
News about TransMedics Group, Inc.
News & sentiment via Polygon.io
